ArticleBMC chemistry2025
A novel one-pot microwave assisted green synthesis of pyridinyl-1,3,5-triazine-2,4-diamine hybrids as potent antimicrobial agents.
Article in BMC chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A novel, green, and efficient microwave-assisted synthesis of pyridinyl-1,3,5-triazine-2,4-diamine hybrids was developed using a one-step, multi-component reaction involving 2-aminopyridine, cyanamide, and aromatic aldehydes/ketones or cyclic ketones under neat reaction conditions. This method offers a simple, high-yield, and environmentally friendly approach with excellent atom economy. In contrast to traditional, more hazardous methods, this process significantly reduces reaction time and complexity. In vitro antimicrobial evaluation revealed that most synthesized compounds exhibited no significant activity against Staphylococcus aureus, Escherichia coli, and Klebsiella pneumoniae, except compound 7b, which showed efficacy against Klebsiella pneumoniae (MIC = 100 µg/mL). Notably, compounds 6a, 6 g, 7b, and 8 displayed antibacterial activity against Proteus mirabilis, and compounds 6c, 7b, and 7c showed antifungal activity against Candida albicans. Docking simulations demonstrated favorable interactions of compounds 6a and 6 g with the urease enzyme, suggesting their potential as bacterial urease inhibitors. Molecular dynamics simulations of the 6 g-urease complex over 25 ns demonstrated stable ligand binding, minimal structural perturbations, and strong interactions with key active site residues, confirming the complex's stability and integrity. ADMET analysis confirmed favorable drug-like properties, including high gastrointestinal absorption and skin permeability, with some compounds displaying central nervous system activity. The Structure-Activity Relationship (SAR) analysis indicated that both triazine and pyridine moieties are critical for enhancing antibacterial properties, particularly through improved binding with the urease enzyme, with hydrophobic substituents and cyclohexyl groups further optimizing antimicrobial efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.